↓ Cooling
Business
🔮 fades ✓
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer’s first drug candidate from its Seagen acquisition, sigvotatug vedotin, failed to meet primary endpoints in a Phase 3 nonsquamous NSCLC trial.